Skip to content
Markets News
Stocks1 min read

Health Canada Clears Cytokinetics’ MYQORZO for Obstructive HCM

Makkler Newsroom
October 19, 2026 · Based on reporting by GlobeNewswire

The Canadian authorization covers adults with symptomatic class II-III disease and follows positive results from a Phase 3 trial.

Key takeaways

  • Health Canada authorized MYQORZO for adults with symptomatic class II-III obstructive HCM.
  • The product monograph carries a boxed warning about heart failure risk.

Cytokinetics said Health Canada has authorized MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), New York Heart Association class II-III. The company said the Canadian decision is the drug’s fifth regulatory approval in less than a year.

The authorization was supported by results from the Phase 3 SEQUOIA-HCM trial. After 24 weeks, patients taking MYQORZO had a greater improvement in exercise capacity than those taking placebo, according to the trial results.

The Canadian product monograph includes a boxed warning about heart failure risk. It calls for echocardiogram checks before and during treatment, and says starting MYQORZO in patients with a left ventricular ejection fraction below 55% is not recommended.

Topics
CYTKMYQORZO
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.